Is cancer incidence modified by SGLT2 inhibitors?
One of the most important achievements of diabetology in the second decade of the 21st century is undoubtedly the introduction of sodium-glucose cotransporter (SGLT2) inhibitors into clinical practice as a new class of glucose-lowering agents for type 2 diabetes. In addition to the glucosuria induce...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | article |
| Lenguaje: | EN RU |
| Publicado: |
Endocrinology Research Centre
2019
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/e2a9284c7a5f48c585b794a470d53010 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:e2a9284c7a5f48c585b794a470d53010 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:e2a9284c7a5f48c585b794a470d530102021-11-14T09:00:22ZIs cancer incidence modified by SGLT2 inhibitors?2072-03512072-037810.14341/DM10119https://doaj.org/article/e2a9284c7a5f48c585b794a470d530102019-10-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/10119https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378One of the most important achievements of diabetology in the second decade of the 21st century is undoubtedly the introduction of sodium-glucose cotransporter (SGLT2) inhibitors into clinical practice as a new class of glucose-lowering agents for type 2 diabetes. In addition to the glucosuria induced by these agents, which is their main pathway for achieving ‘antidiabetic recovery’, other consequences accompany the intake of SGLT2 inhibitors. These pathways, particularly in oncology, have not been extensively studied. Considering the analysis of the previous studies, this report demonstrates, although not significantly, that cancer morbidity in patients with T2DM treated with SGLT2 inhibitors may be organ-specific. In addition, agents within the class of SGLT-2 inhibitors may be useful in several variants of antitumor therapy, but this theory requires further study.Lev M. BersteinEndocrinology Research Centrearticlediabetessglt2 inhibitorsgliflozinsmalignant tumorsmorbiditytreatmentNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 22, Iss 4, Pp 399-402 (2019) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN RU |
| topic |
diabetes sglt2 inhibitors gliflozins malignant tumors morbidity treatment Nutritional diseases. Deficiency diseases RC620-627 |
| spellingShingle |
diabetes sglt2 inhibitors gliflozins malignant tumors morbidity treatment Nutritional diseases. Deficiency diseases RC620-627 Lev M. Berstein Is cancer incidence modified by SGLT2 inhibitors? |
| description |
One of the most important achievements of diabetology in the second decade of the 21st century is undoubtedly the introduction of sodium-glucose cotransporter (SGLT2) inhibitors into clinical practice as a new class of glucose-lowering agents for type 2 diabetes. In addition to the glucosuria induced by these agents, which is their main pathway for achieving ‘antidiabetic recovery’, other consequences accompany the intake of SGLT2 inhibitors. These pathways, particularly in oncology, have not been extensively studied. Considering the analysis of the previous studies, this report demonstrates, although not significantly, that cancer morbidity in patients with T2DM treated with SGLT2 inhibitors may be organ-specific. In addition, agents within the class of SGLT-2 inhibitors may be useful in several variants of antitumor therapy, but this theory requires further study. |
| format |
article |
| author |
Lev M. Berstein |
| author_facet |
Lev M. Berstein |
| author_sort |
Lev M. Berstein |
| title |
Is cancer incidence modified by SGLT2 inhibitors? |
| title_short |
Is cancer incidence modified by SGLT2 inhibitors? |
| title_full |
Is cancer incidence modified by SGLT2 inhibitors? |
| title_fullStr |
Is cancer incidence modified by SGLT2 inhibitors? |
| title_full_unstemmed |
Is cancer incidence modified by SGLT2 inhibitors? |
| title_sort |
is cancer incidence modified by sglt2 inhibitors? |
| publisher |
Endocrinology Research Centre |
| publishDate |
2019 |
| url |
https://doaj.org/article/e2a9284c7a5f48c585b794a470d53010 |
| work_keys_str_mv |
AT levmberstein iscancerincidencemodifiedbysglt2inhibitors |
| _version_ |
1718429497284362240 |